title: FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
abstract: Early therapy response assessment with metabolic imaging is potentially useful to determine prognosis in aggressive lymphoma and, thus, can guide first-line therapy. Forty-eight patients with aggressive lymphoma [24 Hodgkin's disease (HD); 24 non-Hodgkin's lymphoma (NHL)] underwent fluoro-deoxyglucose positron emission tomography (FDG-PET) before chemotherapy (PET1) and at mid-treatment (PET2). Therapeutic response was evaluated using conventional methods at mid-treatment. PET2 results were related to event-free survival (EFS) and overall survival (OS) using Kaplan-Meier analyses. PET1 was positive in all patients. PET2 was negative in 38 patients (18 NHL-20 HD) and positive in 10 (6 NHL-4 HD). Of the PET-negative patients, 61 and 65% achieved complete remission, and only 50 and 25% of PET-positive patients, respectively, for NHL and HD, achieved complete remission. Significant associations were found between PET2 and EFS (p = 0.0006) and OS (p = 0.04) for NHL, and EFS (p < 0.0001) for HD (but not for OS, because no HD patient died). FDG-PET at mid-treatment can predict the outcome of patients with aggressive lymphoma and should be a useful tool to modify an ineffective therapy.
authors.affiliation: Department of Nuclear Medicine, Hospital of the University of Nantes, Place Alexis Ricordeau, 44093, Nantes, France.
authors.forename: Solène
authors.initials: S
authors.lastname: Querellou
authors.forename: Frédéric
authors.initials: F
authors.lastname: Valette
authors.forename: Caroline
authors.initials: C
authors.lastname: Bodet-Milin
authors.forename: Aurore
authors.initials: A
authors.lastname: Oudoux
authors.forename: Thomas
authors.initials: T
authors.lastname: Carlier
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Chatal
authors.forename: Olivier
authors.initials: O
authors.lastname: Couturier
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18